{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T20:20:52Z","timestamp":1777753252309,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bioorg.2026.109721","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:53:25Z","timestamp":1772643205000},"page":"109721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of a pyrimidine-based steroidal FXR agonist for the treatment of metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"174","author":[{"given":"Xiaomin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuwen","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mao","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanrong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109721_bb0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0015","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: how is it different from NAFLD?","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0025","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0030","first-page":"0028","article-title":"First US drug approved for a liver disease surging around the world","author":"Ledford","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109721_bb0035","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109721_bb0040","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.109721_bb0045","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1021\/acs.jmedchem.5c00539","article-title":"Dual modulator of FXR and HSD17B13: revitalizing FXR therapies in MASH","volume":"68","author":"Wei","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0050","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1021\/acs.jmedchem.2c01918","article-title":"Discovery of the first-in-class intestinal restricted FXR and FABP1 dual modulator ZLY28 for the treatment of nonalcoholic fatty liver disease","volume":"66","author":"Ren","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115307","article-title":"Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease","volume":"252","author":"Qin","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107071","article-title":"Discovery of LH10, a novel fexaramine-based FXR agonist for the treatment of liver disease","volume":"143","author":"Huang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0065","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1021\/jm025529g","article-title":"6\u03b1-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity","volume":"45","author":"Pellicciari","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0070","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2026.109721_bb0075","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.109721_bb0080","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatol"},{"key":"10.1016\/j.bioorg.2026.109721_bb0085","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.109721_bb0090","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.14492","article-title":"Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis","volume":"47","author":"Hameed","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109721_bb0095","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.cgh.2021.07.020","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106203","article-title":"Discovery of 12\u03b2-oxygenated oleanolic acid alkyl esters as potent and selective FXR modulators exhibiting hyperglycemia amelioration in vivo","volume":"129","author":"Wang","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0105","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep4.1368","article-title":"Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents","volume":"3","author":"Hernandez","year":"2019","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bioorg.2026.109721_bb0110","article-title":"Characterization of EDP-305, a highly potent and selective farnesoid X receptor agonist, for the treatment of non-alcoholic steatohepatitis","volume":"3","author":"Chau","year":"2019","journal-title":"Int. J. Gastroenterol\u200c."},{"key":"10.1016\/j.bioorg.2026.109721_bb0115","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.109721_bb0120","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep4.1193","article-title":"Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist","volume":"2","author":"Erstad","year":"2018","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.bioorg.2026.109721_bb0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000446057","article-title":"Cholestatic itch management","volume":"50","author":"Mittal","year":"2016","journal-title":"Curr. Probl. Dermatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of pruritus in cholestasis: understanding and treating the itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0135","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0092-8674(01)00483-4","article-title":"A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons","volume":"106","author":"Dong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109721_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108259","article-title":"MAS-related G protein-coupled receptors X (MRGPRX): orphan GPCRs with potential as targets for future drugs","volume":"238","author":"Al Hamwi","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109721_bb0145","doi-asserted-by":"crossref","first-page":"10525","DOI":"10.1073\/pnas.1903316116","article-title":"MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus","volume":"116","author":"Meixiong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2026.109721_bb0150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48431","article-title":"MRGPRX4 is a bile acid receptor for human cholestatic itch","volume":"8","author":"Yu","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.bioorg.2026.109721_bb0155","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109721_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.10.001","article-title":"Structure-guided discovery of bile acid derivatives for treating liver diseases without causing itch","volume":"187","author":"Yang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.109721_bb0165","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S1097-2765(03)00112-6","article-title":"Structural basis for bile acid binding and activation of the nuclear receptor FXR","volume":"11","author":"Mi","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bioorg.2026.109721_bb0170","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1039\/D0RA10657G","article-title":"Research developments in the syntheses, anti-inflammatory activities and structure-activity relationships of pyrimidines","volume":"11","author":"Rashid","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2026.109721_bb0175","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.109721_bb0180","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2026.109721_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpdd.34","article-title":"Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes","volume":"2","author":"Hodge","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.bioorg.2026.109721_bb0190","article-title":"Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2026.109721_bb0195","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatol"},{"key":"10.1016\/j.bioorg.2026.109721_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107686","article-title":"A sinomenine derivative alleviates bone destruction in collagen-induced arthritis mice by suppressing mitochondrial dysfunction and oxidative stress via the NRF2\/HO-1\/NQO1 signaling pathway","volume":"215","author":"Guo","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.109721_bb0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/med.21599","article-title":"Inducible nitric oxide synthase: regulation, structure, and inhibition","volume":"40","author":"Cinelli","year":"2020","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bioorg.2026.109721_bb0210","first-page":"C719","article-title":"Oxidant stress and endothelial cell dysfunction","volume":"280","author":"Lum","year":"2001","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.bioorg.2026.109721_bb0215","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/01.shk.0000158116.77328.1d","article-title":"Coexposure of lead- and lipopolysaccharide-induced liver injury in rats: involvement of nitric oxide-initiated oxidative stress and TNF-alpha","volume":"23","author":"Liu","year":"2005","journal-title":"Shock"},{"key":"10.1016\/j.bioorg.2026.109721_bb0220","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2174\/1871530323666230103153134","article-title":"Immunomodulatory effects of agarwood leaf extract on RAW264.7 murine macrophages","volume":"23","author":"Pang","year":"2023","journal-title":"Endocr. Metab. Immune. Disord. Drug Targets"},{"key":"10.1016\/j.bioorg.2026.109721_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104659","article-title":"Pentacyclic triterpenes with nitric oxide inhibitory activity from potentilla chinensis","volume":"108","author":"Han","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106979","article-title":"The discovery of a new potent FXR agonist based on natural product screening","volume":"143","author":"Yao","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0235","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1177\/0192623310386499","article-title":"Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system","volume":"38","author":"Thoolen","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0240","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatol"},{"key":"10.1016\/j.bioorg.2026.109721_bb0245","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0250","doi-asserted-by":"crossref","first-page":"12786","DOI":"10.1021\/acs.jmedchem.5c00672","article-title":"Discovery of a novel silybin derivative for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"68","author":"Sui","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0255","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1091581811405856","article-title":"The effect of ergothioneine on clastogenic potential and mutagenic activity","volume":"30","author":"Schauss","year":"2011","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0260","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/1091581816653375","article-title":"A safety evaluation of a nature-identical l-ergothioneine in Sprague Dawley rats","volume":"35","author":"Marone","year":"2016","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0265","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41573-024-01084-2","article-title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"24","author":"Do","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.109721_bb0270","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.109721_bb0275","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/0023677215571192","article-title":"The carbon tetrachloride model in mice","volume":"49","author":"Scholten","year":"2015","journal-title":"Lab. Anim."},{"key":"10.1016\/j.bioorg.2026.109721_bb0280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105911","article-title":"Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3","volume":"77","author":"Fan","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bioorg.2026.109721_bb0290","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jhep.2018.03.011","article-title":"A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer","volume":"69","author":"Tsuchida","year":"2018","journal-title":"J. Hepatol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826002579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:02:25Z","timestamp":1777464145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826002579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":58,"alternative-id":["S0045206826002579"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109721","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of a pyrimidine-based steroidal FXR agonist for the treatment of metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109721"}}